Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Cdmo | Rare Historical Photos

Invesco’s ₹16,000 crore midcap fund delivered 426% return in 10 years. Aditya Khemani reveals the strategy

Invesco India Midcap Fund has impressively delivered a 426% return over a decade, showcasing an investment strategy that values robust earnings potential and strong management teams. The fund employs a concentrated portfolio approach with a moderate turnover rate, aiming to compound earnings over three to five years. This blend of…

The Economic Times

Exclusive | How Vijay Kedia turned a Rs 250 Neuland Labs bet into nearly 100x returns

Investor Vijay Kedia's savvy investment in Neuland Laboratories has paid off handsomely, yielding nearly 100x returns. He seized the opportunity during the Covid downturn when stock prices dipped. By concentrating on the company’s promising peptide sector and its CDMO capabilities, Kedia emphasized his tactic of investing in overlooked firms with…

The Economic Times

How PGIM India's Rs 112 crore Healthcare Fund picks CDMO stocks to generate alpha

PGIM India Healthcare Fund generated a 22% return over the past year by over-allocating to high-growth segments like CDMO, specialty pharma, and hospitals. Anandha Padmanabhan shares insights on navigating hospital capacity expansions, China-plus-one opportunities, GLP-1 dynamics, and key stock-selection strategies across healthcare sub-sectors.

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Aarti Pharmalabs shares rally over 33% in two days post Q1 results. What is driving the surge?

Aarti Pharmalabs shares have surged 33% in two days after the company reported a 65.4% year-on-year rise in Q1FY27 profit and 38.7% growth in revenue. The rally was further supported by a Rs 149-crore capex plan to add 405 KL of capacity for its CDMO and intermediate businesses.

The Economic Times

Akums Drugs shares rally 9% hit 52-week high after Q1 results; stock up 67% YTD

Akums Drugs shares rose sharply on Monday to hit a 52-week high after the company reported strong Q1 FY27 results. Revenue rose 13.9% year-on-year, while profit increased 55%. EBITDA grew 35.4%, supported by strong performance in its CDMO business. The stock has gained 67% so far this year.

The Economic Times

Navin Fluorine shares surge 8% after Q1 profit more than doubles. Should you buy, sell or hold?

Navin Fluorine shares surged nearly 8% after the company posted a strong Q1FY27 performance, with profit more than doubling and revenue rising 44% YoY. Elara Securities retained its 'Buy' rating and Rs 9,158 target, citing robust growth in refrigerants, specialty chemicals and CDMO, along with a strong expansion pipeline that…

The Economic Times

India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life Sciences

Indian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like Sai Life Sciences are investing heavily in capacity, anticipating a surge in demand. While regulatory processes mean benefits will be gradual, this supply-chain realignment presents a landmark opportunity for India's CDMO sector,…

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Dark Horse Consulting Group and Altruist Biologics Announce Memorandum of Understanding to Advance Biologics Manufacturing and Development in China

WALNUT CREEK, Calif. and SUZHOU, China, June 03, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Altruist Biologics, a wholly-owned subsidiary of Innovent Biologics and global contract development and manufacturing organization (CDMO) specializing in the development and…

AAP

AI-linked hiring in CDMO industry jumps nearly 3-fold in 2 years: Report

Artificial intelligence skill demand in India's Contract Development and Manufacturing Organisation sector is set to surge. Demand for AI skills in CDMOs will nearly triple between 2023 and 2025. This reflects a significant shift towards automation and advanced capabilities. Manufacturing and operations remain key areas. However, a talent gap is…

The Economic Times

AGC Biologics to Manufacture Teikoku Seiyaku's rhMMP-7 Drug Substance

HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) -- AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc…

AAP

Deepa Jewellers, Cotec Healthcare receive Sebi approval for IPOs

Deepa Jewellers, a B2B hallmarked gold jewellery processor based in Hyderabad, and Cotec Healthcare, a pharmaceutical CDMO, both received SEBI approval for their IPOs. Deepa's IPO includes a Rs 250 crore fresh issue and an offer for sale by promoters.

The Economic Times

Buy the chaos: Why Kashyap Javeri says market volatility is an investor's best friend right now

Fund Manager Kashyap Javeri views market corrections as opportunities, not warnings. He advocates for investing during volatility, highlighting recent payoffs for those who entered fresh positions or topped up existing ones during the March dip. Javeri is strategically investing in auto ancillaries, capital goods, private banks, and pharma (CDMO), while…

The Economic Times

BioHarvest Sciences Q1 Earnings Call Highlights

BioHarvest Sciences (NASDAQ:BHST) reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, plat

MarketBeat

Is Your Portfolio Healthy? Don't Touch This Stock With a Ten-Foot Pole!

Amidst lingering economic uncertainties, pharma contract development company Avid Bioservices (CDMO) has been flashing red flags with deteriorating financial results in the last reported quarter and bleak prospects. Therefore, I think this fundamentally weak stock might be best avoided. Keep reading.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Read How Avid Bioservices Fared In Q4

Avid Bioservices Inc (NASDAQ:CDMO) reported Q4 FY22 sales of $31.2 million, up 13% Y/Y, beating the consensus of $28.96 million. The growth is attributed to an increase in the scope of in-process and completed manufacturing runs and process development revenues. The company signed multiple new project orders during Q4 totaling approximately $44…

Benzinga

Almost 400M COVID-19 Vaccine Doses Lost Due To Emergent's Baltimore Plant Fiasco

According to a recent report from the US House select subcommittee on the coronavirus crisis, Emergent Biosolutions Inc (NYSE:EBS) might have destroyed nearly 400 million doses of COVID-19 vaccines after failing to meet quality standards. Initially, 75 million - 85 million doses of drug substance were said to be destroyed after contamination. "Despite major…

Benzinga

Avid Bioservices's Return On Capital Employed Overview

Pulled from Benzinga Pro data, Avid Bioservices (NASDAQ:CDMO) showed a loss in earnings since Q2, totaling $2.25 million. Sales, on the other hand, increased by 20.68% to $31.51 million during Q3.

Benzinga

Recap: Avid Bioservices Q3 Earnings

Avid Bioservices (NASDAQ:CDMO) reported its Q3 earnings results on Tuesday, March 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Avid Bioservices reported in-line EPS of $0.04 versus an estimate of $0.04.

Get all your
news in one place.

100's of premium titles.
One news app.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.